Individualizing Initial Treatment Selection in EoE

This episode, titled ‘Individualizing Initial Treatment Selection in EoE,’ features panelists discussing how they approach the expanding range of therapeutic options available for eosinophilic esophagitis. The experts review proton pump inhibitors, swallowed topical corticosteroids, biologic therapy, dietary elimination, and dilation, emphasizing that treatment selection should reflect both clinical disease features and the patient's preferences and ability to implement a chosen strategy.

The panel highlights shared decision-making as a central component of initial therapy. Dietary treatment may appeal to patients who prefer a nonpharmacologic approach, but successful implementation depends on available resources and a patient's willingness to make sustained dietary changes. Similarly, medication options differ in administration requirements and practical burden. Faculty explain that treatment should be followed by objective reassessment, with timing varying by approach. Endoscopy and biopsy remain particularly important because symptom improvement may not accurately reflect inflammatory control.

The experts then discuss when biologic therapy enters the treatment pathway. Inadequate objective response, difficulty sustaining another treatment, and adherence challenges may prompt a change in strategy. Other atopic diseases such as asthma or atopic dermatitis can also influence treatment selection because a biologic may address multiple type 2 inflammatory conditions. The panel emphasizes collaboration with allergy and other specialists, including in settings where formal multidisciplinary clinics are unavailable.

In the next episode, ‘Defining Treatment Goals and Mechanisms in EoE,’ panelists will discuss multidimensional disease-control goals and how topical and systemic therapeutic approaches differ mechanistically.